Das ereignisfreie Überleben als Endpunkt, der unter anderem den PSA-Verlauf einbezieht, ist kein Surrogat für das Gesamtüberleben nach Strahlenbehandlung eines lokalisierten Prostatakarzinoms

Event-free survival as a composite endpoint (commonly including PSA progression) is not a surrogate for overall survival after radiotherapy for localized prostate cancer

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Beck M, Böhmer D, Aebersold DM et al (2020) Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer: statement from the DEGRO working group on prostate cancer. Strahlenther Onkol 196:109–116

    Article  Google Scholar 

  2. 2.

    Malone S, Roy S, Eapen L et al (2020) Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial. J Clin Oncol 38:593–601

    CAS  Article  Google Scholar 

  3. 3.

    Xie W, Regan MM, Buyse M et al (2020) Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol 38:3032–3041

    Article  Google Scholar 

  4. 4.

    Xie W, Regan MM, Buyse M et al (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35:3097–3104

    CAS  Article  Google Scholar 

  5. 5.

    Hartman HE, Jackson WC (2020) Surrogate endpoints in localized prostate cancer. Cancer J 26:48–52

    Article  Google Scholar 

  6. 6.

    Bryant AK, McKay RR, Kader AK et al (2019) Subcastrate testosterone nadir and clinical outcomes in intermediate- or high-risk localized prostate cancer. Int J Radiat Oncol Biol Phys 103:1068–1076

    Article  Google Scholar 

  7. 7.

    Dignam JJ, Hamstra DA, Lepor H et al (2019) Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: analysis of randomized trial NRG/RTOG 9202. J Clin Oncol 37:213–221

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Dr. med. Carsten Nieder.

Ethics declarations

Interessenkonflikt

C. Nieder gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nieder, C. Das ereignisfreie Überleben als Endpunkt, der unter anderem den PSA-Verlauf einbezieht, ist kein Surrogat für das Gesamtüberleben nach Strahlenbehandlung eines lokalisierten Prostatakarzinoms. Strahlenther Onkol 197, 164–165 (2021). https://doi.org/10.1007/s00066-020-01716-7

Download citation